RECRUITING

MicroRNA Regulation of Chronic Inflammation During Aging

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an observational study enrolling healthy individuals aged 18-35 and 65y and older to determine the health of immune cells in the blood and how these cells create inflammation and effect health as we age. It is hoped that once the nature of this relationship has been discovered we can more effectively design therapies to reduce this inflammation. The enrollment goal is 40 participants. The study will occur over the course of 1 month which will include a screening visit and a second visit where the participants will undergo an oral glucose tolerance test, blood draws and leg strength \& exercise tests.

Official Title

MicroRNA Regulation of Chronic Inflammation During Aging

Quick Facts

Study Start:2024-11-12

Study Completion:2028-01-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05392582

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Age between 18 - 35y; 65y and older 2. BMI: \<30 kg/m2 3. Ability to sign informed consent 4. For older participant group: Clinical Frailty Scale score \< 3 and Mini-Cog score \> 3 5. Good general medical health, ambulatory and in independent living setting	* History of cardiovascular disease (e.g., CHF, CAD, MI, CVA) * History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes (Treated hypo/hyperthyroid for at least 6 months will be permitted) * History of kidney disease or failure (CKD \> stage 4) * History of vascular disease * Uncontrolled hypertension - Elevated systolic pressure \>150 or a diastolic blood pressure \> 100 * Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma * Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids will be permitted) * Chronic anti-inflammatory medication use (≥ 2 weeks) within 4 weeks of enrollment * Chronic inflammatory conditions (e.g., Rheumatoid Arthritis, Crohn's, fibromyalgia, lupus, colitis) HIV, Hepatitis B and C * History of stroke with motor disability * A recent history (\<12 months) of GI bleed * History of liver disease or AST/ALT 2 times above the normal limit * History of respiratory disease (acute upper respiratory infection, history of chronic lung disease) * Current smokers or current tobacco use * Current pregnancy as determined by positive pregnancy test * Any staff members who report directly to the principal investigators.

Inclusion Criteria

Exclusion Criteria

1. Age between 18 - 35y; 65y and older
2. BMI: \<30 kg/m2
3. Ability to sign informed consent
4. For older participant group: Clinical Frailty Scale score \< 3 and Mini-Cog score \> 3
5. Good general medical health, ambulatory and in independent living setting

* History of cardiovascular disease (e.g., CHF, CAD, MI, CVA)
* History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes (Treated hypo/hyperthyroid for at least 6 months will be permitted)
* History of kidney disease or failure (CKD \> stage 4)
* History of vascular disease
* Uncontrolled hypertension - Elevated systolic pressure \>150 or a diastolic blood pressure \> 100
* Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma
* Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids will be permitted)
* Chronic anti-inflammatory medication use (≥ 2 weeks) within 4 weeks of enrollment
* Chronic inflammatory conditions (e.g., Rheumatoid Arthritis, Crohn's, fibromyalgia, lupus, colitis) HIV, Hepatitis B and C
* History of stroke with motor disability
* A recent history (\<12 months) of GI bleed
* History of liver disease or AST/ALT 2 times above the normal limit
* History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)
* Current smokers or current tobacco use
* Current pregnancy as determined by positive pregnancy test
* Any staff members who report directly to the principal investigators.

Contacts and Locations

Study Contact

Micah Drummond, PhD

CONTACT

801-213-2737

micah.drummond@hsc.utah.edu

Principal Investigator

Micah Drummond

PRINCIPAL_INVESTIGATOR

The University of Utah

Study Locations (Sites)

The University of Utah

Salt Lake City, Utah, 84112

United States

Collaborators and Investigators

Sponsor: University of Utah

Micah Drummond, PRINCIPAL_INVESTIGATOR, The University of Utah

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-12

Study Completion Date2028-01-01

Study Record Updates

Study Start Date2024-11-12

Study Completion Date2028-01-01

Terms related to this study

Additional Relevant MeSH Terms

Chronic Inflammation